Ads
related to: thalidomide for multiple myeloma treatment centers of america- Transform Myeloma
Multiple Myeloma Information
and Resources for HCPs
- Frontline MM Landscape
Evolving 1st-Line MM Care
Towards Improved Outcomes
- Importance of MRD-
The Importance of Achieving MRD
Negativity for Impacting Outcomes
- MRD Negativity FAQs
Frequently Asked Questions
About Minimal Residual Disease
- Transform Myeloma
Search results
Results from the WOW.Com Content Network
DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. [ 1 ] References
Thalidomide is used as a first-line treatment for multiple myeloma in combination with dexamethasone or with melphalan and prednisone to treat acute episodes of erythema nodosum leprosum, as well as for maintenance therapy. [14] [15] The bacterium that causes tuberculosis (TB) is related to leprosy.
Thalidomide: PO: As above. Multiple myeloma, erythema nodosum leprosum and the following orphan indications: graft versus host disease, mycobacterial infection, recurrent aphthous ulcers, severe recurrent aphthous stomatitis, primary brain malignancies, HIV-associated wasting syndrome, Crohn's disease, Kaposi's sarcoma, myelodysplastic syndrome ...
Other areas of concentration include bone marrow transplants, stem cell transplantation, lymphoma, leukemia, multiple myeloma, neuro-oncology, cutaneous malignancy, gastrointestinal, geriatric, head and neck, thoracic, urologic, breast, and gynecologic. [2] As of 2023, Andre Goy is chair and Chief Physician Officer. [3] [4] [5]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
Folkman convinced the patient's doctor to try thalidomide, and that doctor ended up conducting a clinical trial of thalidomide for people with multiple myeloma in which about a third of the subjects responded to the treatment. [10] The results of that trial were published in the New England Journal of Medicine in 1999. [10] [16]
Ads
related to: thalidomide for multiple myeloma treatment centers of america